PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
- Registration Number
- NCT03392181
- Lead Sponsor
- Northwestern University
- Brief Summary
The purpose of this study is to gain understanding of how PET-MR (positron emission tomography-magnetic resonance imaging) using the substance 18F-DCFPyL (PyL) may help in diagnosing prostate cancer and in determining the stage of prostate cancer before surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Male
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 18F-DCFPyL 18F-DCFPyL -
- Primary Outcome Measures
Name Time Method PET/MR versus mp-MRI for the Staging of Newly Diagnosed Prostate Cancer 5 years To determine if PSMA-Targeted PET/MRI improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the molecular mechanism of 18F-DCFPyL in detecting prostate cancer metastases via PET/MRI?
How does PET/MRI with 18F-DCFPyL compare to conventional imaging in prostate cancer staging accuracy?
Which biomarkers correlate with 18F-DCFPyL uptake in prostate cancer for staging prediction?
What are the adverse events associated with 18F-DCFPyL PET/MRI in prostate cancer patients?
Are there alternative PSMA-targeting radiotracers to 18F-DCFPyL for prostate cancer imaging?
Trial Locations
- Locations (1)
Northwestern University
🇺🇸Chicago, Illinois, United States